Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.95 |
| ▸ | TSHR | P16473 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.64 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11610023 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL29766818 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL7218504 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL7218502 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL10340142 | 0.96 | SIGMAR1 (0.98) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL10340144 | 0.96 | SIGMAR1 (0.98) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL10340107 | 0.95 | SIGMAR1 (0.95) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL10340106 | 0.95 | SIGMAR1 (0.95) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL11248186 | 0.87 | SIGMAR1 (0.81) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 | |
| SCHEMBL11457164 | 0.85 | SIGMAR1 (0.77) | SIGMAR1CYP3A4CYP2D6TSHRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221286-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. | 2014-08-07 | — | — | US | disclosed |
| EP-2758053-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | Gilead Sciences, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043925-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | GILEAD SCIENCES, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221286-A1 | SODIUM CHANNEL BLOCKERS REDUCE GLUCAGON SECRETION | IAPP, SCNN1B, GLP1R | SIGMAR1 2750/4885CYP3A4 4236/4885CYP2D6 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.